Format

Send to

Choose Destination
  • Showing results for fernandez-serrano s, dorca j, garcia-vidal c, fernandez-sabe n, carratala j, fernandez-aguera a, corominas m, padrones s, gudiol f, manresa f. effect of corticosteroids on the clinical course of community-acquired pneumonia a randomized controlled trial. crit care. Your search for Fernández-Serrano S, Dorca J, Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Fernández-Agüera A, Corominas M, Padrones S, Gudiol F, Manresa F. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controled trial. Crit Care retrieved no results.
Crit Care. 2011 Mar 15;15(2):R96. doi: 10.1186/cc10103.

Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial.

Author information

1
Respiratory Medicine Department, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Barcelona, Spain.

Abstract

INTRODUCTION:

The benefit of corticosteroids as adjunctive treatment in patients with severe community-acquired pneumonia (CAP) requiring hospital admission remains unclear. This study aimed to evaluate the impact of corticosteroid treatment on outcomes in patients with CAP.

METHODS:

This was a prospective, double-blind and randomized study. All patients received treatment with ceftriaxone plus levofloxacin and methyl-prednisolone (MPDN) administered randomly and blindly as an initial bolus, followed by a tapering regimen, or placebo.

RESULTS:

Of the 56 patients included in the study, 28 (50%) were treated with concomitant corticosteroids. Patients included in the MPDN group show a more favourable evolution of the pO2/FiO2 ratio and faster decrease of fever, as well as greater radiological improvement at seven days. The time to resolution of morbidity was also significantly shorter in this group. Six patients met the criteria for mechanical ventilation (MV): five in the placebo group (22.7%) and one in the MPDN group (4.3%). The duration of MV was 13 days (interquartile range 7 to 26 days) for the placebo group and three days for the only case in the MPDN group. The differences did not reach statistical significance. Interleukin (IL)-6 and C-reactive protein (CRP) showed a significantly quicker decrease after 24 h of treatment among patients treated with MPDN. No differences in mortality were found among groups.

CONCLUSIONS:

MPDN treatment, in combination with antibiotics, improves respiratory failure and accelerates the timing of clinical resolution of severe CAP needing hospital admission.

TRIAL REGISTRATION:

International Standard Randomized Controlled Trials Register, ISRCTN22426306.

PMID:
21406101
PMCID:
PMC3219361
DOI:
10.1186/cc10103
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center